TDP-43: a critical amplifier of Alzheimer's disease beyond amyloid and tau.

Prevalence and outcomes of co-occurring psychiatric and neurological disorders: An atlas based on umbrella review of 81 meta-analyses.

Microglial heterogeneity in neurological disorders: From dynamic states to druggable targets.

Precision functional network imaging-guided transcranial magnetic stimulation: A review of clinical applications through resting-state fMRI.

Hybrid dextran/fibronectin nanogels for brain-targeted mitophagy inducer delivery to alleviate neuroinflammation and neuronal loss of Parkinson's disease.

The role of Th17 cells in the pathogenesis of Parkinson's disease: From immune dysregulation to neurodegeneration.

From adaptive to maladaptive myelination: White matter dynamics in cognition and neurologic disorders.

Adaptive time-frequency decomposition informer for pathological rest tremor sequence prediction.

Crosstalk between cytokines and tryptophan metabolism: Therapeutic potential for immune effector cell-associated neurotoxicity syndrome.

Trafficking of protein kinases to mitochondria: Implications for ischemic stroke.

Microglia crosstalk with T cells in neurodegenerative diseases: pathogenesis and treatment targets.

Somatostatin-induced modulation of microglial activity contributes to mitigating Alzheimer's disease pathology.

Biomimetic and biocompatible MOFs for medical applications: Advances, challenges, and future directions.

An increasing amount of evidence shows that type I interferon response, which is induced by cyclic guanosine monophosphate-adenosine monophosphate synthase (cGAS) and stimulator of interferon genes (STING) is closely associated with health and neuroinflammatory diseases. Abnormal activation or loss of control of the cGAS-STING axis affects the development of neuroinflammation. Thus, we examined its role in major neurological diseases, including traumatic brain injury, Alzheimer's disease, Parkinson's disease, Huntington's disease, multiple sclerosis, herpes simplex encephalitis, and ataxia-telangiectasia. Additionally, targeted intervention of the cGAS-STING axis to control neuroinflammation and treat related diseases has become the focus of current clinical research. This article describes the development of cGAS inhibitors and small molecules that target the cGAS-STING axis and explores the potential applications of STING inhibitors and agonists in clinical research. In summary, the cGAS-STING axis may impact neurological diseases more than a single protein or gene. Future studies should focus on elucidating the functional dynamics and regulatory networks of this axis and delineating its crosstalk with other signaling cascades. These investigations will provide mechanistic insights for developing targeted therapeutic strategies for associated disorders and potentially facilitate drug repurposing across diverse disease contexts.

Beyond acid-base dyshomeostasis: Dynamic instability of neuronal lysosomal pH as a pathogenic mechanism and therapeutic target in neurological diseases.

Transcranial ultrasound stimulation for neuromodulation in movement disorders.

The role and mechanism of METTL14 in regulating pyroptosis via m6A methylation across multiple diseases: A Systematic review.

Systemic and neurologic autoimmune disorders and antibody seropositivity associated with neurosarcoidosis.

Examining adverse effects in a large clinical trial of rTMS application as a treatment for Alzheimer's disease.

Tianwang Buxin Pill improves cognitive function in APP/PS1 mice by reducing neuronal damage and regulating synaptic plasticity.